Immune checkpoint inhibitors (ICIs) blocking cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have shown promising clinical efficacy in patients diagnosed with melanoma [5]. Here, PDCD1 is linked to melanoma.